InflaRx (NASDAQ:IFRX) Rating Increased to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of InflaRx (NASDAQ:IFRXGet Rating) from a hold rating to a buy rating in a report issued on Tuesday, Zacks.com reports. Zacks Investment Research currently has $1.50 price objective on the stock.

According to Zacks, “InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany. “

Other research analysts have also issued reports about the company. HC Wainwright reduced their target price on InflaRx from $10.00 to $7.00 in a report on Friday, May 13th. SVB Leerink reduced their target price on InflaRx from $8.00 to $6.00 and set an outperform rating on the stock in a report on Friday, March 25th. Raymond James reduced their target price on InflaRx from $15.00 to $7.00 in a report on Friday, May 13th. Finally, Guggenheim lowered InflaRx from a buy rating to a neutral rating in a report on Monday, February 28th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Hold and a consensus price target of $4.80.

NASDAQ:IFRX opened at $1.47 on Tuesday. InflaRx has a 12-month low of $1.29 and a 12-month high of $5.69. The firm has a market capitalization of $64.98 million, a P/E ratio of -1.04 and a beta of 0.82. The stock’s fifty day simple moving average is $1.75 and its 200-day simple moving average is $3.09.

InflaRx (NASDAQ:IFRXGet Rating) last posted its quarterly earnings results on Thursday, March 24th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.04. On average, sell-side analysts predict that InflaRx will post -1.32 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC acquired a new stake in shares of InflaRx in the fourth quarter valued at about $48,000. Two Sigma Investments LP acquired a new stake in shares of InflaRx in the third quarter valued at about $29,000. Geode Capital Management LLC acquired a new stake in shares of InflaRx in the third quarter valued at about $49,000. Two Sigma Securities LLC acquired a new stake in shares of InflaRx in the third quarter valued at about $58,000. Finally, D. E. Shaw & Co. Inc. acquired a new stake in shares of InflaRx in the fourth quarter valued at about $129,000. 20.98% of the stock is currently owned by institutional investors and hedge funds.

About InflaRx (Get Rating)

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases.

Further Reading

Get a free copy of the Zacks research report on InflaRx (IFRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.